A prospective phase I/II study to investigate the efficacy and safety of pre-emptive cytomegalovirus adoptive cellular therapy in patients receiving allogeneic haematopoietic stem cell transplant from an unrelated donor

Trial Profile

A prospective phase I/II study to investigate the efficacy and safety of pre-emptive cytomegalovirus adoptive cellular therapy in patients receiving allogeneic haematopoietic stem cell transplant from an unrelated donor

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2017

At a glance

  • Drugs T cell replacement therapy (Primary) ; Foscarnet; Ganciclovir; Valganciclovir
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Therapeutic Use
  • Acronyms CMV-ACE/ASPECT; CMV:ASPECT
  • Sponsors Cell Medica
  • Most Recent Events

    • 24 Jan 2014 Status changed from active, no longer recruiting to completed (closed - follow-up complete) as reported by United Kingdom Clinical Research Network record.
    • 05 Aug 2013 Accrual to date is 144% according to United Kingdom Clinical Research Network.
    • 24 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov. (NCT01220895 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top